Advertisement
ASBP vs SPRO
Which Stock Would AI Choose? Aspire-Lakewood Holdings (ASBP) vs. Spero Therapeutics (SPRO) Stock Comparison
Key Takeaways
- ASBP is a micro-cap company blending sublingual drug-delivery technology with automotive and industrial control systems, while SPRO is a clinical-stage biopharmaceutical focused on multi-drug resistant (MDR) bacterial infections.
- The two names operate at very different scales: ASBP carries a market capitalization near $12 million, whereas SPRO trades near a $65 million valuation with meaningfully higher liquidity.
- SPRO generates substantial contract and licensing-related revenue (roughly $47 million on a trailing basis), while ASBP remains essentially pre-revenue with minimal trailing sales.
- Both stocks have faced pronounced downward pressure over the past year, reflecting challenging market sentiment for small-cap and early-stage biotech equities.
- ASBP has undergone notable corporate actions in recent months, including a 1-for-40 reverse stock split and a corporate name change, which can complicate historical price comparisons.
- For more detail, explore ASBP Major News and ASBP Today's Price Move, as well as SPRO Major News and SPRO Today's Price Move.
- To see how automated strategies are positioning across the market, explore Trending AI Robots.
Introduction
This stock comparison examines two small-cap equities that occupy adjacent corners of the healthcare landscape yet present sharply different risk-and-reward profiles. ASBP is a diversified, essentially pre-revenue enterprise pairing an emerging sublingual drug-delivery platform with a legacy automotive and industrial control-systems business. SPRO is a more mature clinical-stage biopharmaceutical developer advancing antibiotics against multi-drug resistant infections, supported by recurring collaboration and licensing revenue. Traders and investors focused on relative performance, market positioning, and momentum in volatile micro-cap names may find this side-by-side review useful for understanding how each stock has behaved and what is currently driving sentiment.
ASBP Overview and Recent Performance
ASBP, formerly Aspire Biopharma Holdings and now Aspire-Lakewood Holdings, Inc., combines a nano-technology-based sublingual drug-delivery system with engineered control systems for vehicle applications. Its lead prescription candidate targets pain management, alongside a pipeline spanning anxiety, sleep, and supplement formulations. In recent weeks, the company has navigated meaningful corporate restructuring. A 1-for-40 reverse stock split became effective in January 2026, and the firm adopted its current name in September 2026 — events that reshape how historical prices should be interpreted.
Over the past year, the stock has declined substantially, and its very thin float and modest average daily volume contribute to outsized price swings. Trailing financials show minimal revenue and steep operating losses, with a low beta (a measure of volatility relative to the broader market) reflecting limited correlation to major indexes rather than stability. Market sentiment appears tied primarily to corporate-transaction news and the uncertain commercialization path of its drug-delivery technology.
SPRO Overview and Recent Performance
SPRO, Spero Therapeutics, Inc., is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. It develops treatments for multi-drug resistant (MDR) bacterial infections and rare diseases, with lead candidate Tebipenem HBr — an oral carbapenem-class antibiotic — having completed a second Phase 3 trial for complicated urinary tract infections. The company also maintains licensing collaborations, including an agreement with GSK (GlaxoSmithKline) that provided a significant upfront payment.
Unlike its peer, SPRO records substantial trailing revenue from collaborations and contracts, yet the stock has still fallen sharply over the past year and is down more than 50% year-to-date. Recent market activity reflects sustained selling pressure across small-cap biotech, offset in part by the company's cash position and licensing income. Higher share counts and average trading volume give SPRO comparatively greater liquidity than ASBP, though both remain volatile, event-driven names.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies from a much larger library of AI-powered bots that trade thousands of different tickers. Rather than listing every available system, the platform surfaces only those currently best suited to prevailing market conditions. These bots span a wide range of trading styles, strategies, timeframes, performance statistics, and ticker universes, allowing users to compare approaches and historical results. For traders who prefer data-driven, rules-based positioning over discretionary calls, the page offers a practical way to monitor which automated strategies are gaining traction right now. Explore the Trending AI Robots section to review current selections and their performance metrics.
Head-to-Head Comparison
The clearest contrast between these two names is maturity and revenue generation. SPRO has a late-stage clinical asset, established licensing partnerships, and meaningful trailing revenue, positioning it closer to a commercial inflection point. ASBP, by comparison, is pre-revenue and dependent on advancing an early-stage delivery platform while also operating an unrelated industrial segment — a diversified structure that can dilute strategic focus.
On risk factors, ASBP faces higher volatility from an extremely low float, frequent corporate actions, and limited institutional ownership. SPRO carries clinical-trial and regulatory risk tied to its antibiotic pipeline, alongside dependence on collaboration milestones. Sector exposure differs as well: both sit within healthcare, but ASBP blends biotech with consumer-discretionary auto parts, while SPRO is a pure-play biotech. Neither has demonstrated durable positive momentum in recent months, making both largely catalyst-driven.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, liquidity, and near-term catalysts, Tickeron's AI would likely view SPRO as the relatively more favorable setup at present. Its larger market capitalization, higher trading volume, recurring revenue, and defined clinical and licensing catalysts offer a more stable foundation for trend-following systems than ASBP, whose thin float and recent corporate restructuring introduce elevated uncertainty. That said, both names remain under sustained selling pressure, and neither currently exhibits the persistent upward momentum that trend-oriented AI models typically favor. The assessment is therefore probabilistic rather than definitive, reflecting current market positioning rather than a forecast of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASBP is a Hold and SPRO is a Hold.
ASBP in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 02, 2026
ASBP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 17 of 22 cases where ASBP's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ASBP just turned positive on November 10, 2026. Looking at past instances where ASBP's MACD turned positive, the stock continued to rise in 19 of 44 cases over the following month. The odds of a continued upward trend are 43%.
ASBP moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASBP advanced for three days, in 66 of 127 cases, the price rose further within the following month. The odds of a continued upward trend are 52%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ASBP as a result. In 37 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 46%.
The 10-day moving average for ASBP crossed bearishly below the 50-day moving average on November 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 3 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 27%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for ASBP entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.965) is normal, around the industry mean (0.781). P/E Ratio (-1.217) is within average values for comparable stocks, (39.881). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.494). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (28.818) is also within normal values, averaging (49.456).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. ASBP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
SPRO sees its Stochastic Oscillator recovers from oversold territory
On November 09, 2026, the Stochastic Oscillator for SPRO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 69 instances where the indicator left the oversold zone. In 55 of the 69 cases the stock moved higher in the following days. This puts the odds of a move higher at over 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRO advanced for three days, in 152 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRO as a result. In 76 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for SPRO turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 33 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
SPRO moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SPRO crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for SPRO entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.357) is normal, around the industry mean (3.498). P/E Ratio (7.357) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.550) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
SPRO | ||
|---|---|---|
OUTLOOK RATING 1..100 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 48 | |
PRICE GROWTH RATING 1..100 | 82 | |
P/E GROWTH RATING 1..100 | 91 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ASBP | SPRO | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 34% | 1 day ago 80% |
| Momentum ODDS (%) | 1 day ago 46% | 1 day ago 87% |
| MACD ODDS (%) | 1 day ago 43% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 46% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 45% | 1 day ago 87% |
| Advances ODDS (%) | 1 day ago 52% | 3 days ago 73% |
| Declines ODDS (%) | 9 days ago 80% | 10 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 77% | N/A |
| Aroon ODDS (%) | 1 day ago 79% | 1 day ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ASBP’s FA Score shows that 1 FA rating(s) are green while SPRO’s FA Score has 0 green FA rating(s).
- ASBP’s FA Score: 1 green, 4 red.
- SPRO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ASBP’s TA Score shows that 4 TA indicator(s) are bullish while SPRO’s TA Score has 2 bullish TA indicator(s).
- ASBP’s TA Score: 4 bullish, 5 bearish.
- SPRO’s TA Score: 2 bullish, 6 bearish.
Price Growth
ASBP (@Auto Parts: OEM) experienced а +18.92% price change this week, while SPRO (@Biotechnology) price change was -4.67% for the same time period.
The average weekly price growth across all stocks in the @Auto Parts: OEM industry was -3.28%. For the same industry, the average monthly price growth was -7.73%, and the average quarterly price growth was -18.91%.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
ASBP is expected to report earnings on Nov 13, 2026.
SPRO is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Auto Parts: OEM (-3.28% weekly)OEM or Original Equipment Manufacturer of auto parts refers to the original producer of a vehicles components, and so OEM car parts are usually identical to the parts used in producing the vehicle in the first place. OEM parts tend to fit the specifications of a particular model, and their compatibility is often guaranteed by the automaker itself. OEM parts could be more expensive to buy (compared to other vendors’ products) when a consumer goes for replacement. However, increased competition from aftermarket parts/third-party vendors could, in some cases, keep EOM prices in check. The industry might progress further in adopting newer technologies like 3D printing to boost supply chain performance and quality. Aptiv PLC, Magna International Inc. and BorgWarner Inc. are major OEMs for autos.
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ASBP and
Correlation & Price change
A.I.dvisor indicates that over the last year, ASBP has been loosely correlated with SPRO. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ASBP jumps, then SPRO could also see price increases.
| Ticker / NAME | Correlation To ASBP | 1D Price Change % | ||
|---|---|---|---|---|
| ASBP | 100% | +3.35% | ||
| SPRO - ASBP | 42% Loosely correlated | +0.99% | ||
| ALZN - ASBP | 38% Loosely correlated | -2.96% | ||
| DCOY - ASBP | 31% Poorly correlated | -0.91% | ||
| CMPX - ASBP | 28% Poorly correlated | -0.93% | ||
| INTS - ASBP | 27% Poorly correlated | +6.15% | ||
More | ||||
SPRO and
Correlation & Price change
A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with ASBP. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then ASBP could also see price increases.
| Ticker / NAME | Correlation To SPRO | 1D Price Change % | ||
|---|---|---|---|---|
| SPRO | 100% | +0.99% | ||
| ASBP - SPRO | 42% Loosely correlated | +3.35% | ||
| VYGR - SPRO | 36% Loosely correlated | -3.56% | ||
| JAGX - SPRO | 33% Loosely correlated | +10.46% | ||
| SLDB - SPRO | 33% Poorly correlated | +6.00% | ||
| FLNA - SPRO | 33% Poorly correlated | -0.04% | ||
More | ||||